bothell, wa-based biolife solutions, inc. (nasdaq: blfs), is a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers.
Company profile
Ticker
BLFS
Exchange
Website
CEO
Michael Rice
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • GigCapital5 • Outset Medical ...
Former names
CRYOMEDICAL SCIENCES INC
SEC CIK
Corporate docs
Subsidiaries
SAVSU Technologies, Inc. • Arctic Solutions, Inc. • SciSafe Holdings, Inc. • Global Cooling, Inc. • Sexton Biotechnologies, Inc. • BioLife B.V. ...
IRS number
943076866
BLFS stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
31 Aug 23
8-K
Departure of Directors or Certain Officers
16 Aug 23
S-8
Registration of securities for employees
16 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Results of Operations and Financial Condition
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
27 Jul 23
DEF 14A
Definitive proxy
6 Jun 23
8-K
Departure of Directors or Certain Officers
6 Jun 23
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
19 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
Transcripts
BLFS
Earnings call transcript
2023 Q2
8 Aug 23
BLFS
Earnings call transcript
2023 Q1
10 May 23
BLFS
Earnings call transcript
2022 Q4
16 Mar 23
BLFS
Earnings call transcript
2022 Q3
10 Nov 22
BLFS
Earnings call transcript
2022 Q2
10 Aug 22
BLFS
Earnings call transcript
2022 Q1
10 May 22
BLFS
Earnings call transcript
2021 Q4
1 Mar 22
BLFS
Earnings call transcript
2021 Q3
12 Nov 21
BLFS
Earnings call transcript
2021 Q2
13 Aug 21
BLFS
Earnings call transcript
2021 Q1
14 May 21
Latest ownership filings
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 21.43 mm | 21.43 mm | 21.43 mm | 21.43 mm | 21.43 mm | 21.43 mm |
| Cash burn (monthly) | (no burn) | 216.50 k | 5.09 mm | 7.55 mm | 2.57 mm | 89.75 k |
| Cash used (since last report) | n/a | 675.74 k | 15.90 mm | 23.57 mm | 8.03 mm | 280.13 k |
| Cash remaining | n/a | 20.76 mm | 5.53 mm | -2.14 mm | 13.40 mm | 21.15 mm |
| Runway (months of cash) | n/a | 95.9 | 1.1 | -0.3 | 5.2 | 235.7 |
Institutional ownership, Q2 2023
94.2% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 155 |
| Opened positions | 10 |
| Closed positions | 22 |
| Increased positions | 59 |
| Reduced positions | 52 |
| 13F shares | Current |
|---|---|
| Total value | 848.86 bn |
| Total shares | 40.97 mm |
| Total puts | 62.30 k |
| Total calls | 8.70 k |
| Total put/call ratio | 7.2 |
| Largest owners | Shares | Value |
|---|---|---|
| Casdin Capital | 7.72 mm | $170.65 bn |
| BLK Blackrock | 5.36 mm | $118.47 bn |
| Vanguard | 2.56 mm | $56.62 bn |
| Park West Asset Management | 2.08 mm | $45.99 bn |
| Fred Alger Management | 2.07 mm | $45.82 bn |
| Villiger Walter | 1.98 mm | $111.97 mm |
| STT State Street | 1.15 mm | $25.50 bn |
| Palisade Capital Management | 1.13 mm | $25.07 bn |
| IVZ Invesco | 987.59 k | $21.83 bn |
| AMP Ameriprise Financial | 961.11 k | $21.24 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 28 Sep 23 | Berard Todd | Common Stock | Sell | Dispose S | No | Yes | 14.16 | 464 | 6.57 k | 118,014 |
| 28 Sep 23 | Aby J. Mathew | Common Stock | Sell | Dispose S | No | Yes | 14.16 | 659 | 9.33 k | 273,121 |
| 28 Sep 23 | Rice Michael | Common Stock | Sell | Dispose S | No | Yes | 14.16 | 831 | 11.77 k | 418,635 |
| 24 Sep 23 | Geraint Phillips | Common Stock | Grant | Acquire A | No | No | 0 | 221 | 0.00 | 58,995 |
| 24 Sep 23 | Troy Wichterman | Common Stock | Grant | Acquire A | No | No | 0 | 290 | 0.00 | 66,590 |
| 24 Sep 23 | Aby J. Mathew | Common Stock | Grant | Acquire A | No | No | 0 | 802 | 0.00 | 273,780 |
| 24 Sep 23 | Rice Michael | Common Stock | Grant | Acquire A | No | No | 0 | 290 | 0.00 | 419,466 |
News
Top 5 Health Care Stocks That Could Blast Off This Month
21 Aug 23
Stocks That Hit 52-Week Lows On Friday
11 Aug 23
Craig-Hallum Maintains Buy on BioLife Solns, Lowers Price Target to $23
10 Aug 23
Stocks That Hit 52-Week Lows On Thursday
10 Aug 23
TD Cowen Maintains Outperform on BioLife Solns, Lowers Price Target to $25
9 Aug 23
Press releases
BioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business
8 Aug 23
BioLife Solutions to Provide Second Quarter 2023 Financial Results and Business Update on August 8, 2023
27 Jul 23